The MoU outlines partnership in several key areas including co-developing and publishing innovative research, delivering expert lectures, organizing educational events such as hackathons and workshops ...

Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.

With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development. Deep learning in biopharma has come of age. After ...

Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar ...

Insilico Medicine, a developer of artificial intelligence technology for drug discovery, has raised $255 million in series C financing. The investment round is the second this year to top $200 million ...